BENITEC BIOPHRM Beat Consensus Estimates

BENITEC BIOPHRM (BNTC) reported a loss of $0.24 per share on revenue of $0.00 million for the fiscal third quarter ended March 2025. The consensus estimate was a loss of $0.36 per share. The company beat consensus estimates by 33.33%.

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.